You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Prolonged survival in secondary AML (sAML) starts with VYXEOS1

For adults with newly-diagnosed sAML subtypes therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), VYXEOS demonstrated superior OS, higher CR and CR+CRi rates, and a better chance to reach HSCT compared to 7+31,2,a

Median overall survival was 9.6 months for VYXEOS vs 5.9 months for 7+3 (P=0.005; HR=0.69 [0.52, 0.90]) in a Phase 3 trial. Overall rate of HSCTb was 34% for VYXEOS vs 25% for 7+3.1

Phase 3 randomized, multicenter, open-label, active-controlled study of VYXEOS vs cytarabine and daunorubicin (7+3) in patients 60 to 75 years of age with newly-diagnosed t-AML or AML-MRC.1 See full study design

Analysis of overall survival in patients who received HSCT     See results
Couple at farmers market inside liposome

Prolonged survival in secondary AML (sAML) starts with VYXEOS1

For adults with newly-diagnosed sAML subtypes therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), VYXEOS demonstrated superior OS, higher CR and CR+CRi rates, and a better chance to reach HSCT compared to 7+31,2,a

NCCN recommendations

Liposomal daunorubicin and cytarabine (VYXEOS) is the ONLY treatment recommended by NCCN for induction in sAML patients ≥60 years

Learn more

Outpatient administration

Inpatient and outpatient administration options for appropriate patients

Explore

JazzCares

VYXEOS financial assistance and coverage

Discover

Median overall survival was 9.6 months for VYXEOS vs 5.9 months for 7+3 (P=0.005; HR=0.69 [0.52, 0.90]) in a Phase 3 trial. Overall rate of HSCTb was 34% for VYXEOS vs 25% for 7+3.1

Phase 3 randomized, multicenter, open-label, active-controlled study of VYXEOS vs cytarabine and daunorubicin (7+3) in patients 60 to 75 years of age with newly-diagnosed t-AML or AML-MRC.1
See full study design

Approval checkmark

CMS approves new technology add-on payment for VYXEOS

VYXEOS meets the definition of newness, substantial clinical improvement relative to existing therapies, and cost thresholds. Contact your Jazz Access and Reimbursement Manager (ARM) for more information.

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.